Mobile Health Innovative Solutions v. Apple: Voluntary Dismissal in Health Tech Patent Dispute
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Mobile Health Innovative Solutions, LLC v. Apple, Inc. |
| Numéro de dossier | 2:24-cv-00014 (Fed. Cir.) |
| Tribunal | Tribunal fédéral de première instance pour le district Est du Texas |
| Durée | Jan 2024 – Apr 2024 85 days |
| Résultat | Defendant Win — Voluntary Dismissal with Prejudice |
| Brevets en cause | |
| Produits incriminés | Apple Watch, iPhone, HealthKit, Health App ecosystems |
| Avocat du demandeur | Randall T. Garteiser of Garteiser Honea PLLC |
| Avocat de la défense | Mark D. Selwyn and Thomas Sprankling of WilmerHale LLP |
| Juge | Le juge en chef Rodney Gilstrap |
Introduction
In a case resolved in just 85 days, Mobile Health Innovative Solutions, LLC voluntarily dismissed its patent infringement lawsuit against Apple, Inc. with prejudice — surrendering all claims without any disclosed settlement, damages award, or adjudication on the merits. Filed January 10, 2024, and closed April 4, 2024, in the U.S. District Court for the Eastern District of Texas, the dispute centered on U.S. Patent No. 11,468,984B2, covering technology related to “establishing a current load level” in health monitoring devices and applications.
The case (No. 2:24-cv-00014) is a textbook example of a short-lived patent assertion that ended quietly but carries notable strategic and procedural lessons for patent attorneys, in-house IP counsel, and R&D professionals operating in the rapidly evolving mobile health technology space. The voluntary dismissal with prejudice — filed under FRCP 41(a)(1)(A)(i) — effectively forecloses any future reassertion of the same claims against Apple, making this outcome consequential despite its speed.
Aperçu du dossier
Les parties
⚖️ Demandeur
A patent assertion entity (PAE) focused on mobile health technology IP. As a non-practicing entity (NPE), its principal asset is its patent portfolio, making litigation outcomes directly tied to the viability of its patent claims.
🛡️ Défendeur
A global technology leader whose health monitoring features — embedded in Apple Watch, iPhone, and associated HealthKit and Health app ecosystems — regularly attract patent infringement assertions from NPEs and practicing entities alike. Apple’s IP defense posture is well-established and resource-intensive.
Le brevet en cause
This case involved U.S. Patent No. 11,468,984B2, covering technology related to “establishing a current load level” in health monitoring devices and applications.
- • U.S. Patent No. 11,468,984B2 — Devices, methods, and applications for establishing a current load level (Application No. 16/850,984)
Les produits incriminés
The complaint targeted Apple products and software involving device-based health monitoring — specifically concerning methods and applications for load-level assessment. Given Apple’s HealthKit architecture and Apple Watch sensor stack, the accused functionality likely intersected with physiological monitoring or health data processing workflows.
Représentation juridique
Plaintiff: Randall T. Garteiser of Garteiser Honea PLLC — a boutique Texas firm experienced in NPE patent litigation.
Defendant: A formidable 11-attorney team led by Mark D. Selwyn and Thomas Sprankling of WilmerHale LLP (multiple offices), alongside Gillam & Smith, LLP as local Texas counsel. Apple’s defense team size relative to the case’s rapid closure signals an aggressive early posture.
Developing health tech?
Check if your health tech solution might infringe these or related patents before launch.
Le verdict et l'analyse juridique
Chronologie du litige et historique de la procédure
| étape importante | Date |
| Plainte déposée | 10 janvier 2024 |
| Affaire classée | April 4, 2024 |
| Durée totale | 85 jours |
The case was filed in the Eastern District of Texas — historically one of the most plaintiff-friendly patent venues in the United States — before Chief Judge Rodney Gilstrap, one of the nation’s most experienced patent trial judges who presides over a substantial volume of the country’s patent docket annually.
Despite the favorable venue selection, the case closed before any significant procedural milestones: no Markman (claim construction) hearing was scheduled, no summary judgment motions were filed, and no trial date was set. The matter resolved at Docket No. 20 — indicating minimal litigation activity. This compressed timeline strongly suggests that Apple’s early defense posture, likely including pre-answer challenges to the patent’s validity or claim scope, prompted the plaintiff to reassess its litigation position rapidly.
Résultat
The Court accepted and acknowledged a voluntary dismissal with prejudice filed by Mobile Health Innovative Solutions, LLC pursuant to FRCP 41(a)(1)(A)(i). The order was unambiguous:
- • All claims and causes of action against Apple are dismissed with prejudice
- • Chaque partie supporte ses propres frais, dépenses et honoraires d'avocat
- • Toutes les demandes de mesures provisoires en instance sont rejetées pour cause de caducité
No damages were awarded. No injunction was issued. No consent judgment or disclosed settlement agreement accompanied the dismissal.
Signification juridique
While non-precedential on substantive patent law, this case is procedurally instructive:
- FRCP 41(a)(1)(A)(i) as a defense tool: Apple’s rapid assembly of an 11-attorney defense team may have signaled overwhelming litigation costs and early invalidity risks to the plaintiff, triggering the voluntary exit.
- NPE litigation economics in EDTX: Even in a historically plaintiff-favorable venue, resource asymmetry can compel early abandonment.
- Prejudicial dismissal consequences: Patent holders asserting through NPE structures must carefully evaluate whether early withdrawal forecloses valuable IP assets against other defendants in the same technology space.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in mobile health technology. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- Voir tous les brevets liés à ce domaine technologique
- Découvrez quelles entreprises sont les plus actives dans le domaine des brevets liés aux technologies de la santé.
- Comprendre les modèles d'interprétation des revendications
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Health data load-level processing
Brevets associés
In mobile health tech space
Options de contournement
Disponible pour la plupart des réclamations
✅ Points clés à retenir
FRCP 41(a)(1)(A)(i) dismissals with prejudice permanently bar reassertion against the same defendant — counsel clients on downstream consequences before filing.
Rechercher la jurisprudence connexe →Venue selection in EDTX does not guarantee plaintiff advantage when defendant resources are asymmetric.
Explorer les précédents →The absence of § 285 fee shifting here leaves open questions about whether Apple evaluated pursuing exceptional case designation.
Comprendre les indemnités →Monitor patent family members of US11468984B2 for continuation applications that may resurface in future litigation.
Suivre les familles de brevets →Track NPE assertion patterns in mobile health technology for licensing posture adjustments.
Analyser les tendances NPE →Foire aux questions
U.S. Patent No. 11,468,984B2 (Application No. 16/850,984), covering devices, methods, and applications for establishing a current load level in health monitoring contexts.
Plaintiff Mobile Health Innovative Solutions filed a voluntary dismissal under FRCP 41(a)(1)(A)(i). The “with prejudice” designation permanently bars reassertion of the same claims against Apple. No court-adjudicated finding on validity or infringement was issued.
It signals that NPEs asserting health technology patents against well-resourced defendants face significant early economic pressure, potentially limiting assertion strategies and impacting portfolio licensing leverage across the sector.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- PACER — Case No. 2:24-cv-00014, E.D. Tex.
- USPTO Patent Center — U.S. Patent No. 11,468,984B2
- Cornell Legal Information Institute — FRCP 41
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.